DIM N Stock Overview
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Sartorius Stedim Biotech S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4,417.56 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 0.59 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -64.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| DIM N | MX Life Sciences | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how DIM N performed against the MX Life Sciences industry.
Return vs Market: Insufficient data to determine how DIM N performed against the MX Market.
Price Volatility
| DIM N volatility | |
|---|---|
| DIM N Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: DIM N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DIM N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 10,662 | Rene Faber | www.sartorius.com |
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products.
Sartorius Stedim Biotech S.A. Fundamentals Summary
| DIM N fundamental statistics | |
|---|---|
| Market cap | Mex$437.24b |
| Earnings (TTM) | Mex$5.52b |
| Revenue (TTM) | Mex$49.51b |
79.1x
P/E Ratio8.8x
P/S RatioIs DIM N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIM N income statement (TTM) | |
|---|---|
| Revenue | €2.78b |
| Cost of Revenue | €1.54b |
| Gross Profit | €1.23b |
| Other Expenses | €923.80m |
| Earnings | €309.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 18, 2024
| Earnings per share (EPS) | 3.18 |
| Gross Margin | 44.44% |
| Net Profit Margin | 11.16% |
| Debt/Equity Ratio | 133.5% |
How did DIM N perform over the long term?
See historical performance and comparison